#ECTRIMS2019 – Ocrevus Living Up to ‘Game-changing’ Moniker, Genentech’s Hideki Garren Says in Interview
Two years after the approval of Ocrevus (ocrelizumab), the latest data continue to support the benefits of the so-called “game-changing” therapy in multiple sclerosis (MS), while new insights highlight its neuronal protective effects and safety. Multiple Sclerosis News Today had the opportunity to speak with Hideki Garren,…